|
I haven't yet listened to the presentations (am at work right now), but it's interesting that they are reporting only 13% benefit for sequential use of herceptin. I wonder if they perhaps meant ABSOLUTE rather than relative benefit? -- because, of course, HERA (where all subjects were given heceptin AFTER chemo) reported a 46% benefit for those who received herceptin.
Regards,
/Christine
|